Home » Healthcare » Hemophilia Market

Hemophilia Market By Type (Hemophilia A, Hemophilia B, Hemophilia C, Others) By Treatment (On-demand, Prophylaxis) By Therapy (Replacement therapy, ITI therapy, Gene therapy) – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2028

Summary
Table Of Content

How has the Increasing Number of Hemophilia Treatment Centers influenced the Hemophilia Market’s Expansion?

Haemophilia is a genetic condition that impairs the body’s capacity to form clots. A person with hemophilia is more likely to bleed for a more extended period after an injury or cut, has easy bruising, and is more likely to bleed inside joints or the brain. Hemophilia A and B are the two types of the disease. Reduced levels of clotting factor VIII characterize the former, whereas decreased levels of clotting factor IX cause the latter. Other types include parahemophilia, which is brought on by low factor V levels, and hemophilia C, which is brought on by low factor XI levels. Hemophilia affects around 1.125 million people globally. The genetic bleeding illness affects 1,125,000 men worldwide, with 418,000 suffering from a severe form of the generally undetected disease. Hemophilia was formerly considered to affect only 400,000 people worldwide.

The accessibility of limited therapeutic therapy options and the increasing pressure on regulatory authorities have resulted in increased R&D initiatives. There is a growing prevalence of hemophilia treatment centers that attempt to treat impoverished patients. Both public and commercial healthcare organizations are substantially investing in establishing specialist clinics that are set up to fulfill the specific needs of patients. The creation of healthcare centers is expected to promote the growth of the hemophilia market. Furthermore, regulatory agencies are making efforts to raise awareness about the disease and provide information about appropriate therapy.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

What is the Market Size of Hemophilia in terms of Value?

The global Hemophilia Market is projected to increase at a significant CAGR of 4.70% in the coming years. In 2021, the global Hemophilia market was valued at USD 11241.4 million and projected to reach USD 14808.14 million by 2028. The demand for Hemophilia is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD 3566.74 million between 2022 and 2028.

Which Type of Hemophilia is the Most Common?

Hemophilia is classified as hemophilia A, hemophilia B, and others. The classification depends on the patient’s coagulation factor deficit. Type A hemophilia is the most common and is four times more prevalent than type B hemophilia. According to WebMD LLC statistics published in 2019, the incidence of type A varies by country, with a spectrum of 5.4-14.5 instances per 100,000 males. Furthermore, 50-60% of patients had severe hemophilia A, which is linked to high bleeding symptoms. Furthermore, most available products are used to treat type hemophilia A.

The global Hemophilia market was valued at $11241.4 million and is expected to reach $14808.14 million by 2028.

Interesting Facts about Hemophilia Industry

It is anticipated that the total market will expand due to the increased prevalence of bleeding disorders and the increasing severity of those diseases due to genetic evolution. The target population, diagnosis rate, and use of preventive therapy for hemophilia are all on the rise. These factors, together with an increase in R&D studies for therapeutic solutions in the market, all help fuel its expansion.
The North America region dominated the hemophilia market in 2021, and this dominance is expected to continue throughout the forecast period.
Hemophilia therapy involves giving drugs intravenously or nasally to stop internal bleeding that frequently occurs and could lead to infection, arthritis, or joint degeneration.
The government invests more funds in R&D projects, healthcare, and establishing established manufacturers. Rising target patient populations and consumer awareness of technologically advanced products also help the company’s bottom line.

Who are the Top 10 Players/Companies in the Hemophilia market regarding Value?

The major firms in the global hemophilia market value Shire (Baxalta); CSL Behring; Pfizer, Inc.; Genzyme Corporation; Chugai Pharmaceutical Co. Ltd.; Bayer AG; BioMarin, Spark Therapeutics, Inc.; Novo Nordisk A/S.; and Octapharma AG. These essential players are focusing on new product launches as well as technological innovation to increase their hemophilia treatment production and obtain a competitive market share on a global scale. For instance, in 2021, BioMarin Pharmaceutical Inc. announced strong Phase 3 gene therapy study results in adults with severe hemophilia A in the United States. Over the projection period, such continuous R&D initiatives are expected to boost market demand. As a result, the variables described above are expected to boost product acceptance in the country. On the other hand, in December 2020, Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicine firm, announced improved follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, experimental gene therapy for patients with moderate to severe hemophilia A.

Who are the Top 10 Countries in the Hemophilia Market?

The major countries in the global hemophilia market are the US, Canada, Brazil, China, Japan, Australia, India, Indonesia, Malaysia, and the U.K. The frequency of hemophilia varies significantly across the United States. The estimated prevalence of hemophilia A in the United States is 12 cases per 100,000 males and 3.7 cases per 100,000 males for hemophilia B. The primary driver of regional expansion is rising prevalence and a growing preference for preventive treatment. In the United States, this condition is diagnosed at a young age. Furthermore, the government intends to launch early neonatal screening campaigns and other supportive initiatives, increasing demand for hemophilia diagnostic technologies in the United States.

Which is the Key Therapy Segment in the Hemophilia Market?

Replacement treatment is expected to be the largest sector, with gene therapy expected to become the fastest-growing category over the projection period. Replacement therapy is the standard Therapy utilized in the treatments and helps patients replenish lost clotting factors. One of the developing fields is gene therapy, particularly in finding faulty DNA bases and replacing them with functioning ones. AMT-060 is a possible therapeutic developed by UniQure for managing type B diabetes that is now in clinical studies. The Therapy works by introducing a functioning copy of the factor IX gene into liver cells of type B patients to restore factor IX production.

What are the Major Driving Factors for Hemophilia Market?

The rising prevalence of bleeding diseases and their increasing severity due to genetic evolution are expected to boost overall market expansion. The increase in R&D studies for treatment treatments in the segment and the rise in the target population, diagnosis rate, and use of preventive Therapy for hemophilia all contribute to the expansion of the hemophilia treatment market. Conversely, the increased knowledge of hemophilia in emerging nations presents a chance for the hemophilia treatment business to flourish. Rising government awareness campaigns and supported actions are planned to begin early neonatal screening, likely increasing the demand for hemophilia diagnostic equipment. An increase in the prevalence of hemophilia in newborns also drives the growth of the hemophilia market.

What are the Major Restraints for Hemophilia Market?

The high cost of hemophilia therapy, a lack of hemophilia drugs, and significant adverse effects associated with plasma-derived products are projected to limit market expansion. Hemophilia treatment is associated with significant direct expenditures such as hospitalization and pharmacological treatments and substantial indirect costs such as decreased work productivity. The inadequate knowledge in developing and underdeveloped regions restricts market expansion. The market’s growth is hampered by low acceptance rates of technologically sophisticated items.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Which Region Dominated the World Hemophilia Market?

In 2021, North America will dominate the hemophilia market over the forecast period. The primary drivers of this increase are expected to be high prevalence and a growing propensity toward preventive treatment. According to the World Federation of Hospitals’ annual global survey, approximately 64% of patients in the United States have chosen prophylactic treatment. In the United States, this condition is diagnosed at a young age. The region’s rapid expansion can be attributed to a number of factors, including increased government investment in healthcare and R&D activities, as well as the presence of established industries. Rising awareness of technologically advanced items and an expanding target patient pool are also adding to the company’s income.

Due to an increase in hemophilia patients, the Asia-Pacific region is anticipated to grow significantly. Furthermore, rising healthcare costs present a potential prospect for industry expansion. Early disease diagnosis in nations like Japan, India, Indonesia, and Malaysia, as well as increased per capita use of medications for factor VIII and IX insufficiency, are the primary impact delivery drivers. Rising healthcare infrastructure in the region’s growing nations and growth in per capita income are some drivers that will propel the APAC region throughout the forecasted period. Though therapy is costly, with rising disposable income in APAC growing economies such as India and China, people should be able to afford it in the forecasted period.

Segmentation of Global Hemophilia Market-

Global Hemophilia Market – By Type

Hemophilia A
Hemophilia B
Hemophilia C
Others

Global Hemophilia Market – By Treatment

On-demand
Prophylaxis

Global Hemophilia Market – By Therapy

Replacement therapy
ITI therapy
Gene therapy

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Hemophilia Market

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Hemophilia Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Major Industry Challenges
3.2.3. Key Growth Pockets
3.3. Attractive Investment Proposition,2021
3.3.1. Type
3.3.2. Treatment
3.3.3. Therapy
3.3.4. Geography
3.4. Porter’s Five Forces Analysis
3.4.1. Threat of New Entrants
3.4.2. Bargaining Power of Buyers/Consumers
3.4.3. Bargaining Power of Suppliers
3.4.4. Threat of Substitute Types
3.4.5. Intensity of Competitive Rivalry
3.5. Value Chain Analysis

4. Market Positioning of Key Players, 2021
4.1. Company market share of key players, 2021
4.2. Competitive Benchmarking
4.3. Geographical Presence Analysis
4.4. Major Strategies Adopted by Key Players
4.4.1. Key Strategies Analysis
4.4.2. Mergers and Acquisitions
4.4.3. Partnerships
4.4.4. Product Launch
4.4.5. Geographical Expansion
4.4.6. Others

5. COVID 19 Impact Analysis
5.1. Global Hemophilia Market Pre Vs Post COVID 19, 2019 – 2028
5.2. Impact on Import & Export
5.3. Impact on Demand & Supply

6. North America
6.1. North America Hemophilia Market, by Country, 2016-2028(US$ Bn)
6.1.1. U.S.
6.1.2. Canada
6.1.3. Mexico
6.2. North America Hemophilia Market, by Type, 2016-2028(US$ Bn)
6.2.1. Overview
6.2.2. Hemophilia A
6.2.3. Hemophilia B
6.2.4. Hemophilia C
6.2.5. Others
6.3. North America Hemophilia Market, by Treatment, 2016-2028(US$ Bn)
6.3.1. Overview
6.3.2. On-demand
6.3.3. Prophylaxis
6.4. North America Hemophilia Market, by Therapy, 2016-2028(US$ Bn)
6.4.1. Overview
6.4.2. Replacement therapy
6.4.3. ITI therapy
6.4.4. Gene therapy

7. Europe
7.1. Europe Hemophilia Market, by Country, 2016-2028(US$ Bn)
7.1.1. UK
7.1.2. France
7.1.3. Germany
7.1.4. Italy
7.1.5. Russia
7.1.6. Ukraine
7.1.7. Spain
7.1.8. Belgium
7.1.9. Netherland
7.1.10. Austria
7.1.11. Sweden
7.1.12. Poland
7.1.13. Denmark
7.1.14. Switzerland
7.1.15. Rest of Europe
7.2. Europe Hemophilia Market, by Type, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Hemophilia A
7.2.3. Hemophilia B
7.2.4. Hemophilia C
7.2.5. Others
7.3. Europe Hemophilia Market, by Treatment, 2016-2028(US$ Bn)
7.3.1. Overview
7.3.2. On-demand
7.3.3. Prophylaxis
7.4. Europe Hemophilia Market, by Therapy, 2016-2028(US$ Bn)
7.4.1. Overview
7.4.2. Replacement therapy
7.4.3. ITI therapy
7.4.4. Gene therapy

8. Asia Pacific
8.1. Asia Pacific Hemophilia Market, by Country, 2016-2028(US$ Bn)
8.1.1. China
8.1.2. Japan
8.1.3. South Korea
8.1.4. India
8.1.5. Australia
8.1.6. New Zealand
8.1.7. Taiwan
8.1.8. Indonesia
8.1.9. Malaysia
8.1.10. Philippine
8.1.11. Rest of Asia Pacific
8.2. Asia Pacific Hemophilia Market, by Type, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. Hemophilia A
8.2.3. Hemophilia B
8.2.4. Hemophilia C
8.2.5. Others
8.3. Asia Pacific Hemophilia Market, by Treatment, 2016-2028(US$ Bn)
8.3.1. Overview
8.3.2. On-demand
8.3.3. Prophylaxis
8.4. Asia Pacific Hemophilia Market, by Therapy, 2016-2028(US$ Bn)
8.4.1. Overview
8.4.2. Replacement therapy
8.4.3. ITI therapy
8.4.4. Gene therapy

9. Latin America
9.1. Latin America Hemophilia Market, by Country, 2016-2028(US$ Bn)
9.1.1. Brazil
9.1.2. Argentina
9.1.3. Peru
9.1.4. Chile
9.1.5. Colombia
9.1.6. Rest of Latin America
9.2. Latin America Hemophilia Market, by Type, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.2. Hemophilia A
9.2.3. Hemophilia B
9.2.4. Hemophilia C
9.2.5. Others
9.3. Latin America Hemophilia Market, by Treatment, 2016-2028(US$ Bn)
9.3.1. Overview
9.3.2. On-demand
9.3.3. Prophylaxis
9.3.4. Bakery and Confectionery
9.4. Latin America Hemophilia Market, by Therapy, 2016-2028(US$ Bn)
9.4.1. Overview
9.4.2. Replacement therapy
9.4.3. ITI therapy
9.4.4. Gene therapy

10. Middle East
10.1. Middle East Hemophilia Market, by Country, 2016-2028(US$ Bn)
10.1.1. UAE
10.1.2. KSA
10.1.3. Israel
10.1.4. Turkey
10.1.5. Iran
10.1.6. Rest of Middle East
10.2. Middle East Hemophilia Market, by Type, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. Hemophilia A
10.2.3. Hemophilia B
10.2.4. Hemophilia C
10.2.5. Others
10.3. Middle East Hemophilia Market, by Treatment, 2016-2028(US$ Bn)
10.3.1. Overview
10.3.2. On-demand
10.3.3. Prophylaxis
10.3.4. Bakery and Confectionery
10.4. Middle East Hemophilia Market, by Therapy, 2016-2028(US$ Bn)
10.4.1. Overview
10.4.2. Replacement therapy
10.4.3. ITI therapy
10.4.4. Gene therapy

11. Africa
11.1. Africa Hemophilia Market, by Country, 2016-2028(US$ Bn)
11.1.1. South Africa
11.1.2. Egypt
11.1.3. Nigeria
11.1.4. Rest of Africa
11.2. Africa Hemophilia Market, by Type, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. Hemophilia A
11.2.3. Hemophilia B
11.2.4. Hemophilia C
11.2.5. Others
11.3. Africa Hemophilia Market, by Treatment, 2016-2028(US$ Bn)
11.3.1. Overview
11.3.2. On-demand
11.3.3. Prophylaxis
11.3.4. Bakery and Confectionery
11.4. Africa Hemophilia Market, by Therapy, 2016-2028(US$ Bn)
11.4.1. Overview
11.4.2. Replacement therapy
11.4.3. ITI therapy
11.4.4. Gene therapy

12. Global
12.1. Global Hemophilia Market, by Type, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. Hemophilia A
12.1.3. Hemophilia B
12.1.4. Hemophilia C
12.1.5. Others
12.2. Global Hemophilia Market, by Treatment, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. On-demand
12.2.3. Prophylaxis
12.2.4. Bakery and Confectionery
12.3. Global Hemophilia Market, by Therapy, 2016-2028(US$ Bn)
12.3.1. Overview
12.3.2. Replacement therapy
12.3.3. ITI therapy
12.3.4. Gene therapy

13. Company Profiles
13.1. Shire (Baxalta)
13.2. CSL Behring
13.3. Pfizer, Inc.
13.4. Genzyme Corporation
13.5. Chugai Pharmaceutical Co. Ltd.
13.6. Bayer AG
13.7. BioMarin
13.8. Spark Therapeutics, Inc.
13.9. Novo Nordisk A/S.
13.10. Octapharma AG

List of Figures

FIG. 1 Global Hemophilia Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Hemophilia Market Segmentation
FIG. 4 Global Hemophilia Market, by Type, 2021 (US$ Bn)
FIG. 5 Global Hemophilia Market, by Treatment, 2021 (US$ Bn)
FIG. 6 Global Hemophilia Market, by Therapy, 2021 (US$ Bn)
FIG. 7 Global Hemophilia Market, by Geography, 2021 (US$ Bn)
FIG. 8 Attractive Investment Proposition, by Type, 2021
FIG. 9 Attractive Investment Proposition, by Treatment, 2021
FIG. 10 Attractive Investment Proposition, by Therapy, 2021
FIG. 11 Attractive Investment Proposition, by Geography, 2021
FIG. 12 Global Market Positioning of Key Hemophilia Market Manufacturers, 2019
FIG. 13 Global Hemophilia Market Value Contribution, By Type, 2021 & 2028 (Value %)
FIG. 14 Global Hemophilia Market, by Hemophilia A, Value, 2016-2028 (US$ Bn)
FIG. 15 Global Hemophilia Market, by Hemophilia B, Value, 2016-2028 (US$ Bn)
FIG. 16 Global Hemophilia Market, by Hemophilia C, Value, 2016-2028 (US$ Bn)
FIG. 17 Global Hemophilia Market, by Others, Value, 2016-2028 (US$ Bn)
FIG. 18 Global Hemophilia Market Value Contribution, By Treatment, 2021 & 2028 (Value %)
FIG. 19 Global Hemophilia Market, by On-demand, Value, 2016-2028 (US$ Bn)
FIG. 20 Global Hemophilia Market, by Prophylaxis, Value, 2016-2028 (US$ Bn)
FIG. 21 Global Hemophilia Market Value Contribution, By Therapy, 2021 & 2028 (Value %)
FIG. 22 Global Hemophilia Market, by Replacement therapy, Value, 2016-2028 (US$ Bn)
FIG. 23 Global Hemophilia Market, by ITI therapy, Value, 2016-2028 (US$ Bn)
FIG. 24 Global Hemophilia Market, by Gene therapy, Value, 2016-2028 (US$ Bn)
FIG. 25 U.S. Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 26 Rest of North America Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 27 U.K. Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 28 Germany Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 29 France Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 30 Italy Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 31 Spain Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 32 Russia Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 33 BENELUX Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 34 Poland Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 35 Austria Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 36 Rest of Europe Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 37 Japan Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 38 China Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 39 India Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 40 South Korea Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 41 Australia Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 42 Southeast Asia Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 43 Rest of Asia Pacific Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 44 Middle East & Africa Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 45 South Africa Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 46 Nigeria Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 47 Egypt Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 48 GCC Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 49 Israel Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 50 Latin America Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 51 Brazil Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 52 Argentina Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 53 Colombia Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 54 Peru Hemophilia Market, 2016-2028 (US$ Bn)
FIG. 55 Chile Hemophilia Market, 2016-2028 (US$ Bn)

List of Tables

TABLE 1 Market Snapshot: Global Hemophilia Market
TABLE 2 Global Hemophilia Market, by Type, 2016-2028 (US$ Bn)
TABLE 3 Global Hemophilia Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 4 Global Hemophilia Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 5 Global Hemophilia Market, by Geography, 2016-2028 (US$ Bn)
TABLE 6 North America Hemophilia Market, by Type, 2016-2028 (US$ Bn)
TABLE 7 North America Hemophilia Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 8 North America Hemophilia Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 9 North America Hemophilia Market, by Country, 2016-2028 (US$ Bn)
TABLE 10 Europe Hemophilia Market, by Type, 2016-2028 (US$ Bn)
TABLE 11 Europe Hemophilia Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 12 Europe Hemophilia Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 13 Europe Hemophilia Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 14 Asia Pacific Hemophilia Market, by Type, 2016-2028 (US$ Bn)
TABLE 15 Asia Pacific Hemophilia Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 16 Asia Pacific Hemophilia Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 17 Asia Pacific Hemophilia Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 18 Latin America Hemophilia Market, by Type, 2016-2028 (US$ Bn)
TABLE 19 Latin America Hemophilia Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 20 Latin America Hemophilia Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 21 Latin America Hemophilia Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 22 Middle East Hemophilia Market, by Type, 2016-2028 (US$ Bn)
TABLE 23 Middle East Hemophilia Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 24 Middle East Hemophilia Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 25 Middle East Hemophilia Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 26 Africa Hemophilia Market, by Type, 2016-2028 (US$ Bn)
TABLE 27 Africa Hemophilia Market, by Treatment, 2016-2028 (US$ Bn)
TABLE 28 Africa Hemophilia Market, by Therapy, 2016-2028 (US$ Bn)
TABLE 29 Africa Hemophilia Market, by Country/Region, 2016-2028 (US$ Bn)

Frequently Asked Questions

How does COVID-19 Impact the global Hemophilia market?

The global Hemophilia market is expected to be impacted significantly by COVID-19.

Which is the leading market for Hemophilia?

North America accounted for the highest share in the global Hemophilia market in terms of Value.

What are the critical drivers for the growth of the Hemophilia market?

The increasing prevalence and severity of bleeding illnesses due to genetic evolution are predicted to drive overall market growth. The increase in R&D studies for treatment treatments in the segment, as well as the increase in the target population, diagnosis rate, and use of hemophilia preventive therapy, all contribute to the expansion of the hemophilia treatment market.

Which is the primary type segment in Hemophilia Market?

Hemophilia A segment had a significant share in 2021 with more than 40% of the market revenue share.

Which is the primary treatment segment in Hemophilia Market?

The prophylaxis segment had a significant share in 2021, with more than 60% of the market revenue share.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –